What happens with my data? We need your contact details in order to grant you access to the on-demand course. In addition, we evaluate the collected data to optimise the quality of future continuing education events. This form does not work with Internet Explorer 11 or an older version. Thank you for your understanding.


    We would like to invite you to our webinar “Management of lymphoma patients treated with B-cell depleting agents”. Four national speakers will highlight various aspects of B-cell depletion in lymphoma, specifically in DLBCL (diffuse large B-cell lymphoma), and the potential secondary immunodeficiencies that may result.

    For questions or concerns, please contact:

    Dr. Christoph Schneider
    Head of Marketing & Sales CSL Behring
    079 580 57 49

    Dr. Simone Gruber
    Medical Advisor Incyte
    079 658 56 83

    Note: The webinar is intended for healthcare professionals only.

    Your opinion counts!

    (1=min, 10=max)

      Quality of the content

      Quality of the presentation

      How likely are you to recommend this event to a colleague?


      17:00 –17:05WelcomeChair
      17:05 –17:352nd-line treatment of patients with DLBCL not eligible for intensive optionsPD Dr. Jeroen Goede, Kantonsspital Winterthur
      17:35–18:05Difficulties in handling R/R DLBCL patients with B-cell targeting agents: Challenging patient casesDr. Noémie Lang, HUG Genève
      18:05–18:10Discussion part I
      18:10–18:40Immunological aspects during B-cell depletionDr. Urs Steiner, Inselspital Bern
      18:40–19:10Management of secondary immunodeficiencies in the hemato-oncological settingDr. Nathan Cantoni, Kantonsspital Aarau
      19:10–19:15Discussion part II

      Organized and sponsored by

      Legal notice

      CSL Behring and Incyte have engaged POMCANYS Marketing AG to conduct the webinar/webcast. For information on how your personal data is processed click on the following links for CSL Behring and Incyte.
      Please note that by participating in the webcast it can be concluded that you are entering into a customer relationship with CSL Behring and/or Incyte Biosciences.

      CSL Behring AG, Wankdorfstrasse 10, CH-3014 Bern / Incyte Biosciences International Sàrl, Rue Docteur-Yersin 12 CH-1110 Morges